Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

Core Insights - Revelation Biosciences, Inc. has successfully submitted and received acceptance for the end-of-phase 1 meeting package to the FDA [1] - The company is on track to hold the meeting later this year, which aims to gather agency feedback on the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI) [1] Company Developments - The primary focus of the meeting with the FDA is to establish feedback regarding the clinical development of Gemini [1] - The company is positioned as a clinical-stage life sciences entity concentrating on rebalancing inflammation [1]